LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q2 2024
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 191 | +4 | 666.78M | $798.87B | +6 | −3 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 21.81M | — | $19.75B | 3.2% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.65M | — | $18.70B | 2.2% | n/c | 1 | SEC ↗ ×2 |
| 3 | PRIMECAP Management ✦ | 19.62M | — | $17.76B | 12.9% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (pasif) | 17.01M | — | $15.35B | 1.3% | n/c | 1 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (pasif) | 11.00M | — | $9.96B | 1.5% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 10.78M | — | $9.76B | 1.7% | n/c | 1 | SEC ↗ ×9 |
| 7 | Fisher Asset Management ✦ | 4.89M | — | $4.43B | 1.9% | n/c | 1 | SEC ↗ |
| 8 | Arrowstreet Capital ✦ | 1.61M | — | $1.46B | 1.3% | n/c | 1 | SEC ↗ |
| 9 | Tiger Global Management ✦ | 930.00K | — | $842.00M | 3.9% | n/c | 1 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 827.68K | — | $749.37M | 1.4% | n/c | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 789.56K | — | $714.85M | 1.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 532.04K | — | $481.70M | 0.4% | n/c | 1 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 500.83K | — | $453.45M | 0.5% | n/c | 1 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 474.55K | — | $429.65M | 0.7% | n/c | 1 | SEC ↗ ×5 |
| 15 | D. E. Shaw & Co. ✦ | 237.22K | — | $214.78M | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 225.78K | — | $204.42M | 0.5% | n/c | 1 | SEC ↗ |
| 17 | Coatue Management ✦ | 207.05K | — | $187.46M | 0.7% | n/c | 1 | SEC ↗ ×4 |
| 18 | Viking Global Investors ✦ | 144.18K | — | $130.53M | 0.5% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 95.74K | — | $86.68M | 0.5% | n/c | 1 | SEC ↗ |
| 20 | Dodge & Cox ✦ | 45.98K | — | $41.63M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | GAMCO Investors ✦ | 35.83K | — | $32.44M | 0.4% | n/c | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 11.95K | — | $10.82M | 0.1% | n/c | 1 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 4,323 pemegang, 762.84M saham, $674.93B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Tidak ada pembelian insider di pasar terbuka dalam jendela cakupan kami.
Penjualan di pasar terbuka (S)
Officer · 6.50K lbr · $7.64M
Officer · 2.00K lbr · $2.37M
Officer · 5.00K lbr · $5.95M
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi